Treatment-free molecular remission achieved by combination therapy with imatinib and IFNα in CML with <i>BIM</i> deletion polymorphism relapsed after stop imatinib

Bibliographic Information

Other Title
  • Imatinib中止後の再発にimatinibとIFNα併用療法を行い無治療で分子寛解を維持する<i>BIM</i>欠失多型のCML
  • 症例報告 第1回日本血液学会関東甲信越地方会 会長推薦演題 Imatinib中止後の再発にimatinibとIFNα併用療法を行い無治療で分子寛解を維持するBIM欠失多型のCML
  • ショウレイ ホウコク ダイ1カイ ニホン ケツエキ ガッカイ カントウ コウシンエツチホウカイ カイチョウ スイセン エンダイ Imatinib チュウシ ゴ ノ サイハツ ニ imatinib ト IFNaヘイヨウ リョウホウ オ オコナイ ムチリョウ デ ブンシカンカイ オ イジ スル BIM ケツシツタケイ ノ CML

Search this article


A 51-year-old man with chronic myeloid leukemia (CML) was treated with imatinib (IM). After 24 months of treatment, he achieved a complete molecular response (CMR), which he sustained for 3 years. However, 4 months after discontinuing IM treatment, the CML relapsed. The patient was treated again with IM and achieved CMR. A combination of IM and interferon-α (IFNα) was administered for the following year, and then discontinued. The patient has since sustained CMR without therapy for 24 months, to date. This patient was found to have a BCL2L11 (BIM) deletion polymorphism. CML patients with a BIM deletion polymorphism show a low response to IM, and we infer that the BIM deletion polymorphism is a negative factor for discontinuation of IM. IFNα treatment is expected to prevent relapse during immunological surveillance. Therefore, the combination of IM and IFNα might be a feasible approach for CML patients who experience difficulty with IM discontinuation.


  • Rinsho Ketsueki

    Rinsho Ketsueki 56 (2), 216-219, 2015

    The Japanese Society of Hematology

Related Projects

See more

Details 詳細情報について

Report a problem

Back to top